Blinding
Blinding of the investigators would necessitate blinding towards the TTV load in the active group and towards the TAC trough levels in both groups. TAC dosing would have to be done centralised. It is unlikely that such trial design would be accepted by the investigator. Thus, we decided against blinding of the investigators.